Statins and ischemic stroke

Atherosclerosis Supplements

Volumn 3, Issue 1, 2002, Pages 21-25

  Liao, James K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cholesterol; Endothelium; G proteins; Gene regulation; Isoprenoids; Nitric oxide; Stroke

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISOPRENOID; ISOPRENOID PHOSPHATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; PLEIOTROPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; HYPERCHOLESTEROLEMIA; META ANALYSIS; METABOLISM; REVIEW; UPREGULATION; VASCULAR ENDOTHELIUM;

CEREBROVASCULAR ACCIDENT; CHOLESTEROL; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; META-ANALYSIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLYISOPRENYL PHOSPHATES; UP-REGULATION;

EID: 0036583443     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00011-3     Document Type: Conference Paper

References (41)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339:1998;1349-1357.
3. Packard C.J. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole, TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
5. Klag M.J., Ford D.E., Mead L.A., He J., Whelton P.K., Liang K.Y., Levine D.M. Serum cholesterol in young men and subsequent cardiovascular disease. N. Engl. J. Med. 328:1993;313-318.
6. Blum C.B. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am. J. Cardiol. 73:1994;3D-11D.
7. Massy Z.A., Keane W.F., Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet. 347:1996;102-103.
8. Shepherd J, Cobbe SM, Ford, I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
9. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
10. Pekkanen J., Linn S., Heiss G., Suchindran C.M., Leon A., Rifkind B.M., Tyroler H.A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 322:1990;1700-1707.
11. Liao J.K. Endothelium and acute coronary syndromes. Clin. Chem. 44:1998;1799-1808.
12. Selwyn A.P., Kinlay S., Libby P., Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 95:1997;5-7.
13. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Invest. 100:1997;2153-2157.
14. Munzel T., Sayegh H., Freeman B.A., Tarpey M.M., Harrison D.G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J. Clin. Invest. 95:1995;187-194.
15. Tamai O., Matsuoka H., Itabe H., Wada Y., Kohno K., Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation. 95:1997;76-82.
16. Anderson T.J., Meredith I.T., Yeung A.C., Frei B., Selwyn A.P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332:1995;488-493.
17. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
18. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 332:1995;481-487.
19. Laufs U., Fata V.L., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 272:1997;31725-31729.
20. Laufs U., Fata V.L., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
21. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
22. Van Aelst L., D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 11:1997;2295-2322.
23. Aktories K. Bacterial toxins that target Rho proteins. J. Clin. Invest. 99:1997;827-829.
24. Hall A. Rho GTPases and the actin cytoskeleton. Science. 279:1998;509-514.
25. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273:1998;24266-24271.
26. Laufs U., Liao J.K. Targeting rho in cardiovascular disease. Circ. Res. 87:2000;526-528.
27. Laufs U., Endres M., Stagliano N., Amin-Hanjani S., Chui D.S., Yang S.X., Simoncini T., Yamada M., Rabkin E., Allen P.G., Huang P.L., Bohm M., Schoen F.J., Moskowitz M.A., Liao J.K. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J. Clin. Invest. 106:2000;15-24.
28. Patrono C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 330:1994;1287-1294.
29. Caplan L.R. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 341:1999;1240-1241.
30. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333:1995;1581-1587.
31. Crouse J.R., Byington R.P., Furberg C.D. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 138:1998;11-24.
32. Multiple risk factor intervention trial. Risk factor changes and mortality results. J. Am. Med. Assoc. 248:1982;1465-1477.
33. Sytkowski P.A., Kannel W.B., D'Agostino R.B. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N. Engl. J. Med. 322:1990;1635-1641.
34. Dalkara T., Yoshida T., Irikura K., Moskowitz M.A. Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology. 33:1994;1447-1452.
35. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 377:1995;239-242.
36. Huang Z., Huang P.L., Ma J., Meng W., Ayata C., Fishman M.C., Moskowitz M.A. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J. Cereb. Blood Flow Metab. 16:1996;981-987.
37. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 95:1998;8880-8885.
38. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 6:2000;1004-1010.
39. Lefer A.M., Campbell B., Shin Y.K., Scalia R., Hayward R., Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 100:1999;178-184.
40. Hernandez-Perera O., Perez-Sala D., Soria E., Lamas S. Involvement of rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ. Res. 87:2000;616-622.
41. Essig M., Nguyen G., Prie D., Escoubet B., Sraer J.D., Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ. Res. 83:1998;683-690.